RY 158.42 -2.3365% SHOP 106.88 -7.7667% TD 81.285 -1.6396% ENB 62.25 -2.5364% BN 67.38 -5.0049% TRI 240.23 -3.0471% CNQ 38.91 -7.4673% CP 100.18 0.9675% CNR 138.81 0.318% BMO 128.11 -5.3211% BNS 66.41 -2.5961% CSU 4403.5898 -2.5664% CM 80.03 -3.6248% MFC 39.89 -7.6193% ATD 71.08 -2.6568% NGT 63.19 -7.1964% TRP 65.305 -4.8864% SU 47.03 -9.261% WCN 273.28 -2.9304% L 207.78 -0.8494%
Last update at 2025-04-04T16:48:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -103.23800M | -56.12600M | -35.88800M | -17.26813M | -18.17282M |
| Minority interest | 14.26M | 5.78M | -2.36900M | -0.81400M | -0.16151M |
| Net income | -101.29400M | -50.34700M | -34.32900M | -15.93131M | -17.96875M |
| Selling general administrative | 41.04M | 25.57M | 12.39M | 7.66M | 6.31M |
| Selling and marketing expenses | 19.32M | 8.89M | - | - | - |
| Gross profit | -3.23700M | -0.08500M | - | - | 0.00000M |
| Reconciled depreciation | 2.46M | 0.23M | 0.02M | 0.01M | 0.00979M |
| Ebit | -90.92700M | -54.39300M | -23.35100M | -14.29529M | -12.08114M |
| Ebitda | -92.80200M | -54.16700M | -23.98800M | -15.38992M | -12.07136M |
| Depreciation and amortization | -1.87500M | 0.23M | -0.63700M | -1.09463M | 0.00979M |
| Non operating income net other | - | -1.73300M | -12.53700M | -2.97284M | -7.60962M |
| Operating income | -90.92700M | -54.39300M | -23.35100M | -14.29529M | -10.56320M |
| Other operating expenses | 91.30M | 54.89M | 23.35M | 14.30M | 10.56M |
| Interest expense | 1.27M | 5.78M | 0.05M | 0.03M | 2.39M |
| Tax provision | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Interest income | - | - | - | 0.59M | 5.59M |
| Net interest income | -1.27200M | 0.00000M | -0.71300M | -0.58292M | -3.00739M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -1.94400M | -5.77900M | -1.55900M | -1.33682M | -0.20407M |
| Total revenue | 0.38M | 0.50M | 0.00000M | 0.00000M | 0.00000M |
| Total operating expenses | 87.69M | 54.31M | 23.35M | 14.30M | 10.56M |
| Cost of revenue | 3.61M | 0.58M | - | - | 0.00000M |
| Total other income expense net | -12.31100M | -1.73300M | -12.53700M | -2.97284M | -4.60223M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -103.23800M | -56.12600M | -35.88800M | -17.26813M | -18.17282M |
| Net income applicable to common shares | -89.26400M | -50.63000M | -34.56300M | -16.72700M | -18.75080M |
| Preferred stock and other adjustments | - | - | - | - | 0.03M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 33.12M | 53.98M | 86.98M | 19.78M | 7.24M |
| Intangible assets | 1.42M | 3.44M | 2029.00M | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 3.78M | 3.90M | 0.53M | 0.85M | 328284.00M |
| Total liab | 57.14M | 43.05M | 7.56M | 20.25M | 11.88M |
| Total stockholder equity | -53.83100M | -9.68100M | 61.67M | 1.90M | -3.82385M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 6.63M | 3.71M | 4.26M | 0.05M | 1.39M |
| Common stock | 0.00900M | 0.10M | 0.09M | 0.06M | 0.04M |
| Capital stock | 3.00M | 2.79M | 2.50M | 2.60M | 2.34M |
| Retained earnings | -294.43300M | -228.16900M | -138.91000M | -88.27500M | -53.71475M |
| Other liab | - | - | - | - | - |
| Good will | - | - | -2026.97100M | - | - |
| Other assets | 0.00000M | 1.12M | 0.72M | 0.84M | 0.69M |
| Cash | 19.64M | 39.74M | 77.26M | 17.26M | 6.22M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 54.18M | 41.20M | 7.56M | 19.95M | 11.88M |
| Current deferred revenue | - | - | - | 2.27M | - |
| Net debt | 29.09M | -3.10700M | -77.25800M | -2.29600M | 1.92M |
| Short term debt | 45.77M | 34.79M | - | 14.66M | 8.14M |
| Short long term debt | 44.20M | 33.65M | - | 14.66M | 8.14M |
| Short long term debt total | 48.73M | 36.64M | - | 14.96M | 8.14M |
| Other stockholder equity | 3230.60M | 215.70M | 198.07M | 87.57M | 47.55M |
| Property plant equipment | - | 5.49M | 1.58M | 0.08M | 0.69M |
| Total current assets | 24.50M | 43.93M | 82.64M | 18.94M | 6.55M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | -15.82100M | 57.22M | -0.64100M | -6.12000M |
| Short term investments | 2.67M | - | - | - | - |
| Net receivables | 0.06M | 0.02M | 0.20M | - | - |
| Long term debt | - | - | - | 0.30M | - |
| Inventory | 1.02M | 0.26M | 4.65M | 0.85M | - |
| Accounts payable | 1.79M | 2.70M | 3.30M | 2.97M | 2.35M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | 17.75M | -2.36900M | -0.81428M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -2993.00000M | - | - | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 0.09M | 0.06M | 0.04M |
| Preferred stock total equity | - | - | 2.42M | 2.54M | 2.30M |
| Retained earnings total equity | - | - | -138.91000M | -88.27500M | -53.71475M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 1.15M | 1.12M | 0.72M | 0.84M | 0.69M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 8.62M | 10.05M | 4.34M | 0.84M | 0.69M |
| Capital lease obligations | 4.53M | 2.99M | - | - | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -4.74000M | -3.71600M | -0.05500M | -0.02720M | -0.02661M |
| Change to liabilities | -0.74200M | 2.09M | 0.50M | 0.67M | 1.50M |
| Total cashflows from investing activities | -4.74000M | -3.71600M | -0.05500M | -0.02720M | -0.02661M |
| Net borrowings | 35.23M | -14.81600M | 16.70M | 6.21M | -5.00000M |
| Total cash from financing activities | 38.21M | 104.31M | 33.01M | 11.38M | 15.50M |
| Change to operating activities | -0.15700M | -1.54000M | -0.41800M | -0.67722M | 0.47M |
| Net income | -103.23800M | -56.12600M | -35.88800M | -17.26813M | -18.17282M |
| Change in cash | -37.51400M | 60.00M | 11.04M | -2.00289M | 6.69M |
| Begin period cash flow | 77.26M | 17.26M | 6.22M | 8.22M | 1.54M |
| End period cash flow | 39.74M | 77.26M | 17.26M | 6.22M | 8.22M |
| Total cash from operating activities | -70.98500M | -40.59100M | -21.91400M | -13.35727M | -8.78791M |
| Issuance of capital stock | 1.89M | 117.02M | 16.03M | 5.55M | 4.41M |
| Depreciation | 2.46M | 0.23M | 0.02M | 0.01M | 0.00979M |
| Other cashflows from investing activities | - | -2.24700M | - | - | - |
| Dividends paid | - | 436.00M | 0.36M | 67436.00M | 0.00710M |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | 0.18M | -0.20000M | -0.20000M | -0.20000M | -0.20000M |
| Sale purchase of stock | -0.36600M | 436.00M | 0.36M | 67436.00M | 16.44M |
| Other cashflows from financing activities | 36.69M | 2.26M | 17.57M | 6.20M | -0.33911M |
| Change to netincome | 16.26M | 15.14M | 12.26M | 1.57M | 2.73M |
| Capital expenditures | 1.54M | 1.47M | 0.06M | 0.03M | 0.03M |
| Change receivables | - | -0.20000M | - | - | - |
| Cash flows other operating | - | -1.72500M | 10.49M | 1.66M | -13.02707M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | 60.00M | 11.04M | -2.00289M | 6.69M |
| Change in working capital | -0.71600M | -1.56600M | 0.08M | -0.06393M | 1.35M |
| Stock based compensation | 19.53M | 15.01M | 2.04M | 1.57M | 1.23M |
| Other non cash items | 10.98M | -1.54900M | 5.33M | 0.56M | 3.10M |
| Free cash flow | -72.52500M | -42.06000M | -21.96900M | -13.38447M | -8.81452M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| PAVM PAVmed Inc |
-0.0613 9.29% | 0.60 | - | - | 7.22 | 7.42 | 20.30 | -0.6573 |
| ABT Abbott Laboratories |
-5.795 4.40% | 125.83 | 37.15 | 23.15 | 4.67 | 4.97 | 4.88 | 19.38 |
| SYK Stryker Corporation |
-18.15 4.93% | 350.00 | 44.07 | 24.94 | 5.51 | 6.12 | 6.05 | 25.73 |
| MDT Medtronic PLC |
-3.5 3.98% | 84.39 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| BSX Boston Scientific Corp |
-7.495 7.61% | 91.00 | 68.17 | 24.57 | 5.85 | 4.26 | 6.46 | 26.80 |
PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
360 Madison Avenue, New York, NY, United States, 10017
| Name | Title | Year Born |
|---|---|---|
| Dr. Lishan Aklog M.D. | Chairman & CEO | 1966 |
| Mr. Dennis M. McGrath CPA | Pres, CFO & Corp. Sec. | 1957 |
| Dr. Brian J. deGuzman M.D. | Chief Medical Officer & Exec. VP of Clinical Affairs | 1965 |
| Mr. Shaun M. O'Neill M.B.A. | Exec. VP & COO | 1982 |
| Mr. Adrian K. Miller | VP of Investor Relations | NA |
| Mr. Dennis M. McGrath CPA | President, CFO & Corporate Secretary | 1957 |
| Mr. Shaun M. O'Neill M.B.A. | Executive VP & COO | 1983 |
| Dr. Brian J. deGuzman M.D. | Executive VP, Chief Technology & Compliance Officer | 1965 |
| Dr. Suman M. Verma M.D., Ph.D. | Senior VP of Molecular Genetics & Chief Scientific Officer | NA |
| Michael Parks | Vice President of Investor Relations | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA
AU
UK
US
NZ
IND
Please wait processing your request...